New aspects of developing a dry powder inhalation formulation applying the quality-by-design approach

Edina Pallagi, Keyhaneh Karimi, Rita Ambrus, P. Szabó-Révész, Ildikó Csóka

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The current work outlines the application of an up-to-date and regulatory-based pharmaceutical quality management method, applied as a new development concept in the process of formulating dry powder inhalation systems (DPIs). According to the Quality by Design (QbD) methodology and Risk Assessment (RA) thinking, a mannitol based co-spray dried formula was produced as a model dosage form with meloxicam as the model active agent. The concept and the elements of the QbD approach (regarding its systemic, scientific, risk-based, holistic, and proactive nature with defined steps for pharmaceutical development), as well as the experimental drug formulation (including the technological parameters assessed and the methods and processes applied) are described in the current paper. Findings of the QbD based theoretical prediction and the results of the experimental development are compared and presented. Characteristics of the developed end-product were in correlation with the predictions, and all data were confirmed by the relevant results of the in vitro investigations. These results support the importance of using the QbD approach in new drug formulation, and prove its good usability in the early development process of DPIs. This innovative formulation technology and product appear to have a great potential in pulmonary drug delivery.

Original languageEnglish
Pages (from-to)151-160
Number of pages10
JournalInternational Journal of Pharmaceutics
Volume511
Issue number1
DOIs
Publication statusPublished - Sep 10 2016

Fingerprint

Powders
Inhalation
Drug Compounding
meloxicam
Pharmaceutical Preparations
Dosage Forms
Mannitol
Technology
Lung
In Vitro Techniques

Keywords

  • Dry powder inhalation
  • Meloxicam
  • Microcomposite
  • Pulmonary administration
  • Quality by design
  • Risk assessment

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

New aspects of developing a dry powder inhalation formulation applying the quality-by-design approach. / Pallagi, Edina; Karimi, Keyhaneh; Ambrus, Rita; Szabó-Révész, P.; Csóka, Ildikó.

In: International Journal of Pharmaceutics, Vol. 511, No. 1, 10.09.2016, p. 151-160.

Research output: Contribution to journalArticle

Pallagi, Edina ; Karimi, Keyhaneh ; Ambrus, Rita ; Szabó-Révész, P. ; Csóka, Ildikó. / New aspects of developing a dry powder inhalation formulation applying the quality-by-design approach. In: International Journal of Pharmaceutics. 2016 ; Vol. 511, No. 1. pp. 151-160.
@article{b99d7f82915c4686b481b28ec063878a,
title = "New aspects of developing a dry powder inhalation formulation applying the quality-by-design approach",
abstract = "The current work outlines the application of an up-to-date and regulatory-based pharmaceutical quality management method, applied as a new development concept in the process of formulating dry powder inhalation systems (DPIs). According to the Quality by Design (QbD) methodology and Risk Assessment (RA) thinking, a mannitol based co-spray dried formula was produced as a model dosage form with meloxicam as the model active agent. The concept and the elements of the QbD approach (regarding its systemic, scientific, risk-based, holistic, and proactive nature with defined steps for pharmaceutical development), as well as the experimental drug formulation (including the technological parameters assessed and the methods and processes applied) are described in the current paper. Findings of the QbD based theoretical prediction and the results of the experimental development are compared and presented. Characteristics of the developed end-product were in correlation with the predictions, and all data were confirmed by the relevant results of the in vitro investigations. These results support the importance of using the QbD approach in new drug formulation, and prove its good usability in the early development process of DPIs. This innovative formulation technology and product appear to have a great potential in pulmonary drug delivery.",
keywords = "Dry powder inhalation, Meloxicam, Microcomposite, Pulmonary administration, Quality by design, Risk assessment",
author = "Edina Pallagi and Keyhaneh Karimi and Rita Ambrus and P. Szab{\'o}-R{\'e}v{\'e}sz and Ildik{\'o} Cs{\'o}ka",
year = "2016",
month = "9",
day = "10",
doi = "10.1016/j.ijpharm.2016.07.003",
language = "English",
volume = "511",
pages = "151--160",
journal = "International Journal of Pharmaceutics",
issn = "0378-5173",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - New aspects of developing a dry powder inhalation formulation applying the quality-by-design approach

AU - Pallagi, Edina

AU - Karimi, Keyhaneh

AU - Ambrus, Rita

AU - Szabó-Révész, P.

AU - Csóka, Ildikó

PY - 2016/9/10

Y1 - 2016/9/10

N2 - The current work outlines the application of an up-to-date and regulatory-based pharmaceutical quality management method, applied as a new development concept in the process of formulating dry powder inhalation systems (DPIs). According to the Quality by Design (QbD) methodology and Risk Assessment (RA) thinking, a mannitol based co-spray dried formula was produced as a model dosage form with meloxicam as the model active agent. The concept and the elements of the QbD approach (regarding its systemic, scientific, risk-based, holistic, and proactive nature with defined steps for pharmaceutical development), as well as the experimental drug formulation (including the technological parameters assessed and the methods and processes applied) are described in the current paper. Findings of the QbD based theoretical prediction and the results of the experimental development are compared and presented. Characteristics of the developed end-product were in correlation with the predictions, and all data were confirmed by the relevant results of the in vitro investigations. These results support the importance of using the QbD approach in new drug formulation, and prove its good usability in the early development process of DPIs. This innovative formulation technology and product appear to have a great potential in pulmonary drug delivery.

AB - The current work outlines the application of an up-to-date and regulatory-based pharmaceutical quality management method, applied as a new development concept in the process of formulating dry powder inhalation systems (DPIs). According to the Quality by Design (QbD) methodology and Risk Assessment (RA) thinking, a mannitol based co-spray dried formula was produced as a model dosage form with meloxicam as the model active agent. The concept and the elements of the QbD approach (regarding its systemic, scientific, risk-based, holistic, and proactive nature with defined steps for pharmaceutical development), as well as the experimental drug formulation (including the technological parameters assessed and the methods and processes applied) are described in the current paper. Findings of the QbD based theoretical prediction and the results of the experimental development are compared and presented. Characteristics of the developed end-product were in correlation with the predictions, and all data were confirmed by the relevant results of the in vitro investigations. These results support the importance of using the QbD approach in new drug formulation, and prove its good usability in the early development process of DPIs. This innovative formulation technology and product appear to have a great potential in pulmonary drug delivery.

KW - Dry powder inhalation

KW - Meloxicam

KW - Microcomposite

KW - Pulmonary administration

KW - Quality by design

KW - Risk assessment

UR - http://www.scopus.com/inward/record.url?scp=84978240394&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978240394&partnerID=8YFLogxK

U2 - 10.1016/j.ijpharm.2016.07.003

DO - 10.1016/j.ijpharm.2016.07.003

M3 - Article

C2 - 27386791

AN - SCOPUS:84978240394

VL - 511

SP - 151

EP - 160

JO - International Journal of Pharmaceutics

JF - International Journal of Pharmaceutics

SN - 0378-5173

IS - 1

ER -